Lars B. Abrahmsen has sold APRE and made no open-market buys since Sep 2021

Dr. Lars B. Abrahmsen is a biochemist and pharmaceutical executive who serves as Senior Vice President and Chief Scientific Officer at Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company developing synthetic lethality-based cancer therapeutics.( He has held this role since October 2014, overseeing nonclinical science activities and translational science support for Aprea’s oncology programs targeting DNA damage response pathways.( As a corporate insider, he has reported equity transactions in Aprea Therapeutics in his capacity as SVP, Chief Scientific Officer.(

Abrahmsen brings more than three decades of experience in oncology-focused drug discovery and development, having led multiple projects from discovery through preclinical development and into the clinic, including work on antibody and protein therapeutics and conjugation technologies.( Before joining Aprea, he served as Chief Scientific Officer at Affibody AB, Senior Vice President Protein Therapeutics at Algeta ASA, and VP Preclinical Development & CSO at KDevOncology, alongside prior roles at Genentech and academic research positions.( He is also Senior Consultant at AABIO AB, providing pharmaceutical R&D consulting in small molecules, antibodies, and protein pharmaceuticals.( Abrahmsen holds an MSc in Chemistry and a PhD in Biochemistry from the KTH Royal Institute of Technology in Stockholm, Sweden.(

Written by Perplexity from public sources.